Agenus (NASDAQ: AGEN) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Insider and Institutional Ownership

37.9% of Agenus shares are held by institutional investors. Comparatively, 42.0% of Abeona Therapeutics shares are held by institutional investors. 7.6% of Agenus shares are held by company insiders. Comparatively, 6.8% of Abeona Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Agenus and Abeona Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agenus $22.57 million 15.71 -$126.99 million ($1.17) -3.03
Abeona Therapeutics $890,000.00 833.10 -$21.87 million ($0.65) -24.38

Abeona Therapeutics has lower revenue, but higher earnings than Agenus. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Agenus and Abeona Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agenus 0 1 2 0 2.67
Abeona Therapeutics 0 0 9 0 3.00

Agenus presently has a consensus price target of $6.33, suggesting a potential upside of 78.91%. Abeona Therapeutics has a consensus price target of $27.00, suggesting a potential upside of 70.35%. Given Agenus’ higher probable upside, research analysts clearly believe Agenus is more favorable than Abeona Therapeutics.

Volatility & Risk

Agenus has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 2.36, suggesting that its share price is 136% more volatile than the S&P 500.

Profitability

This table compares Agenus and Abeona Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Agenus -278.76% N/A -65.18%
Abeona Therapeutics -2,946.58% -27.69% -25.32%

Summary

Abeona Therapeutics beats Agenus on 8 of the 14 factors compared between the two stocks.

About Agenus

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company’s discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company’s vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with Analyst Ratings Network's FREE daily email newsletter.